1-20 of 90
antagonists
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Building the Glucagon-Like Peptide-1 Receptor Brick by Brick: Revisiting a 1993 Diabetes Classic by Thorens et al.

Bernard Thorens, David J. Hodson
Journal: Diabetes
Diabetes 2024;73(7):1027–1031
https://doi.org/10.2337/dbi24-0025
Published: 20 June 2024
View article titled, Building the Glucagon-Like Peptide-1 Receptor Brick by Brick: Revisiting a 1993 <em>Diabetes</em> Classic by Thorens et al.
Open the PDF for Building the Glucagon-Like Peptide-1 Receptor Brick by Brick: Revisiting a 1993 <em>Diabetes</em> Classic by Thorens et al. in another window
Journal Articles

Chronic Glucocorticoid Exposure Induced an S1PR2-RORγ Axis to Enhance Hepatic Gluconeogenesis in Male Mice

Rebecca A. Lee, Maggie Chang, Ariel Tsay, Yeong Rim Lee, Danielle Li, Nicholas Yiv, Sharon Tian, Michelle Zhao, Richard M. O’Brien, Jen-Chywan Wang
Journal: Diabetes
Diabetes 2023;72(11):1534–1546
https://doi.org/10.2337/db22-0605
Published: 08 August 2023
View article titled, Chronic Glucocorticoid Exposure Induced an S1PR2-RORγ Axis to Enhance Hepatic Gluconeogenesis in Male Mice
Open the PDF for Chronic Glucocorticoid Exposure Induced an S1PR2-RORγ Axis to Enhance Hepatic Gluconeogenesis in Male Mice in another window
Journal Articles

Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism

Sean M. Peterson, Christine A. Juliana, Cameron F. Hu, Jinghua Chai, Carson Holliday, Kara Y. Chan, Ana G. Lujan Hernandez, Zoe Challocombe, Linya Wang, Zhen Han, Nikhil Haas, Ryan Stafford, Fumiko Axelrod, Tom Z. Yuan, Diva D. De León, Aaron K. Sato
Journal: Diabetes
Diabetes 2023;72(9):1320–1329
https://doi.org/10.2337/db22-1039
Published: 26 June 2023
View article titled, Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism
Open the PDF for Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism in another window
Meeting Abstracts

842-P: Development of Long-Acting GLP-1 Receptor Antagonist for the Treatment of Congenital Hyperinsulinism

YUE YUAN, HAOWEN JIANG, SHI MENG, DONGNA HAN, QIUSHA ZHU, MANCHEN WANG, HUSHAN LI, JIA LI, CHANGHONG LI
Journal: Diabetes
Diabetes 2023;72(Supplement_1):842-P
https://doi.org/10.2337/db23-842-P
Published: 20 June 2023
View article titled, 842-P: Development of Long-Acting GLP-1 Receptor Antagonist for the Treatment of Congenital Hyperinsulinism
Meeting Abstracts

1-LB: Evaluating the Effectiveness of the Novel Somatostatin Receptor Antagonist (SSTR2a) ZT-01 for Hypoglycemia Prevention in a Rodent Model of Type 2 Diabetes

NINOSCHKA C. D'SOUZA, JULIAN AIKEN, EMILY G. HOFFMAN, SARA C. ATHERLEY, SABRINA CHAMPSI, NADIA ALEALI, DORSA SHAKERI, MAYA EL-ZAHED, NICKY AKBARIAN, MEHRAN NEJAD-MANSOURI, RICHARD LIGGINS, OWEN CHAN, MICHAEL C. RIDDELL, PARINAZ ZAREE BAVANI
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1-LB
https://doi.org/10.2337/db23-1-LB
Published: 20 June 2023
View article titled, 1-LB: Evaluating the Effectiveness of the Novel Somatostatin Receptor Antagonist (SSTR2a) ZT-01 for Hypoglycemia Prevention in a Rodent Model of Type 2 Diabetes
Meeting Abstracts

219-OR: Glucagon Counterregulation in a Hypoglycemic Clamp in Type 1 Diabetes Is Increased by ZT-01, a Novel Somatostatin Receptor 2 Antagonist—A Phase 1b Study

ALEXANDER ABITBOL, SUSAN PEERS, ERIC SIMONSON, MICHAEL MIDMER, MICHAEL RIDDELL, RICHARD LIGGINS
Journal: Diabetes
Diabetes 2023;72(Supplement_1):219-OR
https://doi.org/10.2337/db23-219-OR
Published: 20 June 2023
View article titled, 219-OR: Glucagon Counterregulation in a Hypoglycemic Clamp in Type 1 Diabetes Is Increased by ZT-01, a Novel Somatostatin Receptor 2 Antagonist—A Phase 1b Study
Meeting Abstracts

431-P: Effects of CB1 Antagonist INV-202 in Patients with Metabolic Syndrome—A Randomized, Placebo-Controlled, Double-Blind Phase 1B Study

GLENN D. CRATER, FRANCOIS RAVENELLE, KARINE LALONDE, JEAN-PIERRE DESPRÉS
Journal: Diabetes
Diabetes 2023;72(Supplement_1):431-P
https://doi.org/10.2337/db23-431-P
Published: 20 June 2023
View article titled, 431-P: Effects of CB1 Antagonist INV-202 in Patients with Metabolic Syndrome—A Randomized, Placebo-Controlled, Double-Blind Phase 1B Study
Journal Articles

Comment on Tabatabaei Dakhili et al. The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase. Diabetes 2023;72:126–134

Gavin P. Reynolds
Journal: Diabetes
Diabetes 2023;72(5):e5
https://doi.org/10.2337/db23-0088
Published: 20 April 2023
View article titled, Comment on Tabatabaei Dakhili et al. The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase. Diabetes 2023;72:126–134
Open the PDF for Comment on Tabatabaei Dakhili et al. The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase. Diabetes 2023;72:126–134 in another window
Journal Articles

The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase

Seyed Amirhossein Tabatabaei Dakhili, Amanda A. Greenwell, Kunyan Yang, Rabih Abou Farraj, Christina T. Saed, Keshav Gopal, Jordan S.F. Chan, Jadin J. Chahade, Farah Eaton, Crystal Lee, Carlos A. Velázquez-Martínez, Peter A. Crawford, J.N. Mark Glover, Rami Al Batran, John R. Ussher
Journal: Diabetes
Diabetes 2023;72(1):126–134
https://doi.org/10.2337/db22-0221
Published: 18 October 2022
View article titled, The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase
Open the PDF for The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase in another window
Journal Articles

Dopamine Negatively Regulates Insulin Secretion Through Activation of D1-D2 Receptor Heteromer

Fumiya Uefune, Toru Aonishi, Tetsuya Kitaguchi, Harumi Takahashi, Susumu Seino, Daisuke Sakano, Shoen Kume
Journal: Diabetes
Diabetes 2022;71(9):1946–1961
https://doi.org/10.2337/db21-0644
Published: 22 June 2022
View article titled, Dopamine Negatively Regulates Insulin Secretion Through Activation of D1-D2 Receptor Heteromer
Open the PDF for Dopamine Negatively Regulates Insulin Secretion Through Activation of D1-D2 Receptor Heteromer in another window
Meeting Abstracts

1197-P: Effect of Somatostatin Receptor 2 Antagonist (SSTR2a) on Glycemia and Glucagon Levels in a Rat Model of Type 2 Diabetes (T2D)

NINOSCHKA C. D'SOUZA, EMILY G. HOFFMAN, SARA C. ATHERLEY, SABRINA CHAMPSI, MARIYA POPKOV, RICHARD LIGGINS, MICHAEL RIDDELL
Journal: Diabetes
Diabetes 2021;70(Supplement_1):1197-P
https://doi.org/10.2337/db21-1197-P
Published: 01 June 2021
View article titled, 1197-P: Effect of Somatostatin Receptor 2 Antagonist (SSTR2a) on Glycemia and Glucagon Levels in a Rat Model of Type 2 Diabetes (T2D)
Meeting Abstracts

236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

JEREMY PETTUS, SCHAFER C. BOEDER, MARK P. CHRISTIANSEN, DOUGLAS S. DENHAM, TIMOTHY S. BAILEY, HALIS K. AKTURK, LESLIE J. KLAFF, JULIO ROSENSTOCK, MICKIE H.M. CHENG, BRUCE W. BODE, EDGAR D. BAUTISTA, HAI YAN, DUNG THAI, SATISH K. GARG, SAMUEL KLEIN
Journal: Diabetes
Diabetes 2021;70(Supplement_1):236-OR
https://doi.org/10.2337/db21-236-OR
Published: 01 June 2021
View article titled, 236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Journal Articles

Emerging Role of Bone Morphogenetic Protein 4 in Metabolic Disorders

Ritesh K. Baboota, Matthias Blüher, Ulf Smith
Journal: Diabetes
Diabetes 2021;70(2):303–312
https://doi.org/10.2337/db20-0884
Published: 14 January 2021
View article titled, Emerging Role of Bone Morphogenetic Protein 4 in Metabolic Disorders
Open the PDF for Emerging Role of Bone Morphogenetic Protein 4 in Metabolic Disorders in another window
Journal Articles

Acyl-Ghrelin Influences Pancreatic β-Cell Function by Interference with KATP Channels

Julia Kaiser, Peter Krippeit-Drews, Gisela Drews
Journal: Diabetes
Diabetes 2021;70(2):423–435
https://doi.org/10.2337/db20-0231
Published: 05 November 2020
View article titled, Acyl-Ghrelin Influences Pancreatic β-Cell Function by Interference with K<sub>ATP</sub> Channels
Open the PDF for Acyl-Ghrelin Influences Pancreatic β-Cell Function by Interference with K<sub>ATP</sub> Channels in another window
Meeting Abstracts

1725-P: Viral Insulins as Agonists and Antagonists on Insulin/IGF-1 Receptors

FRANCOIS MOREAU, BRUNA BRANDAO, ESQ., CARLY CEDERQUIST, THIAGO M. BATISTA, RICHARD DIMARCHI, EMRAH ALTINDIS, C. RONALD KAHN
Journal: Diabetes
Diabetes 2020;69(Supplement_1):1725-P
https://doi.org/10.2337/db20-1725-P
Published: 01 June 2020
View article titled, 1725-P: Viral Insulins as Agonists and Antagonists on Insulin/IGF-1 Receptors
Meeting Abstracts

9-LB: Novel Somatostatin Receptor 2 Antagonist ZT-01 Prevents Hypoglycemia Onset in STZ-Diabetic Rats by Improving Glucagon Secretion

JULIAN AIKEN, NINOSCHKA C. D’SOUZA, ERIC SIMONSON, RAWAD FARHAT, OWEN CHAN, RICHARD LIGGINS, MICHAEL RIDDELL
Journal: Diabetes
Diabetes 2020;69(Supplement_1):9-LB
https://doi.org/10.2337/db20-9-LB
Published: 01 June 2020
View article titled, 9-LB: Novel Somatostatin Receptor 2 Antagonist ZT-01 Prevents Hypoglycemia Onset in STZ-Diabetic Rats by Improving Glucagon Secretion
Meeting Abstracts

1909-P: The Natriuretic Action of Glucagon-Like Peptide-1 in Humans Is Abolished by the GLP-1 Receptor Antagonist Exendin 9-39

ALI ASMAR, PER K. CRAMON, MEENA ASMAR, LENE SIMONSEN, STEN MADSBAD, CHARLOTTE M. SORENSEN, BOLETTE HARTMANN, JENS J. HOLST, PETER HOVIND, BOYE L. JENSEN, JENS BÜLOW
Journal: Diabetes
Diabetes 2020;69(Supplement_1):1909-P
https://doi.org/10.2337/db20-1909-P
Published: 01 June 2020
View article titled, 1909-P: The Natriuretic Action of Glucagon-Like Peptide-1 in Humans Is Abolished by the GLP-1 Receptor Antagonist Exendin 9-39
Meeting Abstracts

12-LB: Subcutaneous Administration of the Novel Somatostatin Receptor 2 Antagonist ZT-01 Restores the Glucagon Response to Hypoglycemia in STZ-Diabetic Rats to Normal Levels

RAWAD FARHAT, ERIC SIMONSON, MICHAEL RIDDELL, RICHARD LIGGINS, OWEN CHAN
Journal: Diabetes
Diabetes 2020;69(Supplement_1):12-LB
https://doi.org/10.2337/db20-12-LB
Published: 01 June 2020
View article titled, 12-LB: Subcutaneous Administration of the Novel Somatostatin Receptor 2 Antagonist ZT-01 Restores the Glucagon Response to Hypoglycemia in STZ-Diabetic Rats to Normal Levels
Meeting Abstracts

1745-P: Inhibition of Soluble Epoxide Hydrolase 1 (sEH1) Improves Glucose Tolerance and Decreases Diabetes Incidence

TAYLEUR WHITE, SASANKA RAMANADHAM, BRUCE HAMMOCK
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1745-P
https://doi.org/10.2337/db19-1745-P
Published: 01 June 2019
View article titled, 1745-P: Inhibition of Soluble Epoxide Hydrolase 1 (sEH1) Improves Glucose Tolerance and Decreases Diabetes Incidence
Meeting Abstracts

1761-P: Brain-Restricted CB1-Receptor Antagonists Increase Oxygen Consumption Rate and Promote Beiging in 3T3-L1 Adipocytes Similar to Rimonabant Suggesting that Central Effects Can Be Avoided

REBECCA K. PASZKIEWICZ, RICHARD N. BERGMAN, AARON FRANK, ORISON O. WOOLCOTT, ROBERTA DE SOUZA SANTOS, MALINI S. IYER, DEBORAH CLEGG, MORVARID KABIR
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1761-P
https://doi.org/10.2337/db19-1761-P
Published: 01 June 2019
View article titled, 1761-P: Brain-Restricted CB1-Receptor Antagonists Increase Oxygen Consumption Rate and Promote Beiging in 3T3-L1 Adipocytes Similar to Rimonabant Suggesting that Central Effects Can Be Avoided